CD8A and ovarian carcinoma: In 2010, Wu et al. observed a significant increase of CD8+ T cells and a decrease in regulatory T cells (Treg) at day 12–14 after one cycle of adjuvant carboplatin–paclitaxel in 13 patients with advanced primary epithelial ovarian cancer [35].